

# US Conviction List - Directors' Cut

## July 2025 Update

### US Conviction List - Directors' Cut

See the list >

CL

We add Duke Energy (DUK), Huntington Ingalls (HII) and Kontoor Brands (KTB) to the US Conviction List, while removing Cloudflare (NET), Snowflake (SNOW), and Woodward (WWD). We have a brief summary of these adds below, and include a more detailed write-up within, along with market commentary, a review of list performance, as well as earnings and non-earnings catalysts.

**Steven Kron**  
+1(212)902-1896 | steven.kron@gs.com  
Goldman Sachs & Co. LLC

**Chris Hussey**  
+1(212)902-7564 | chris.hussey@gs.com  
Goldman Sachs & Co. LLC

**John Marshall**  
+1(212)902-6848 | john.marshall@gs.com  
Goldman Sachs & Co. LLC

**Sarah Herr**  
+1(212)357-0094 | sarah.herr@gs.com  
Goldman Sachs & Co. LLC

### Exhibit 1: Conviction List - Directors' Cut July Update

All price targets are 12-months; Prices are as of 6/30; green indicates new

Ticker	Company	Mkt Cap (\$bn)	Price	Price Tgt	% upside	GS vs. Cons* **	Street % Buy
<b>Consumer</b>							
KTB	Kontoor Brands Inc	3.7	\$66	\$85	29%	8%	67%
PM	Philip Morris International	283.5	\$182	\$190	4%	2%	68%
<b>Financials</b>							
BAC	Bank Of America Corp	356.4	\$47	\$56	18%	-1%	79%
COF	Capital One Financial Corp	136.1	\$213	\$250	18%		75%
HUI	Houlihan Lokey Inc	12.6	\$180	\$207	15%	-4%	38%
MAA	Mid-America Apartment Comm	17.3	\$148	\$192	30%	1%	45%
RJF	Raymond James Financial Inc	30.9	\$153	\$173	13%	5%	29%
<b>Healthcare</b>							
ALNY	Alnylam Pharmaceuticals Inc	42.5	\$326	\$378	16%		73%
BAX	Baxter International Inc	15.5	\$30	\$37	22%	4%	35%
INSM	Insmid Inc	19.1	\$101	\$112	11%	9%	100%
JNJ	Johnson & Johnson	367.5	\$153	\$176	15%	1%	54%
<b>Industrial</b>							
AL	Air Lease Corp	6.5	\$58	\$69	18%	2%	86%
DE	Deere & Co	137.7	\$508	\$610	20%	7%	46%
GEV	GE Vernova Inc	144.4	\$529	\$570	8%	6%	70%
HII	Huntington Ingalls Industries	9.5	\$241	\$265	10%	4%	40%
<b>Natural Resources</b>							
DUK	Duke Energy Corp	91.7	\$118	\$132	12%	1%	45%
KGS	Kodiak Gas Services Inc	3.0	\$34	\$43	25%	0%	92%
OLED	Universal Display Corp	7.3	\$154	\$183	18%	4%	67%
VNOM	Viper Energy Inc	11.0	\$38	\$56	47%	23%	100%
<b>TMT</b>							
OS	Onestream Inc	6.8	\$28	\$33	17%	1%	90%
PINS	Pinterest Inc- Class A	24.3	\$36	\$42	17%	3%	81%
T	AT&T	208.2	\$29	\$31	7%	0%	70%
UBER	Uber Technologies Inc	195.1	\$93	\$110	18%	2%	76%

\*EPS:AL,ALNY,BAC,BAX,COF,DE,DUK,HII,HUI,JNJ,KTB,PINS,PM,RJF,VNOM;FFO:MAA;EBITDA:GEV,KGS,OLED,T,UBER;Rev:INSM,OS

\*\*Excludes ALNY GS vs Cons comparison for this period due to inconsistent consensus information & COF due to lack of comparability due to merger

Source: Goldman Sachs Global Investment Research, Bloomberg

For **DUK**, Carly Davenport sees the company making regulatory progress in key markets, while also developing greater electricity generation capacity on the back of

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to [www.gs.com/research/hedge.html](http://www.gs.com/research/hedge.html). Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S. This report is intended for distribution to GS institutional clients only.

# Table of Contents

Market Commentary - so much for sell in May...	4
Conviction List - what has worked, what has not and what has changed	8
Anatomy of the List	11
Conviction List Explained - refrain	13
Our 23 most differentiated Buy recommendations	14
Duke Energy Corp. (DUK) - covered by Carly Davenport	15
Huntington Ingalls Industries Inc. (HII) - covered by Noah Poponak	17
Kontoor Brands Inc. (KTB) - covered by Brooke Roach	20
Disclosure Appendix	22

For the exclusive use of CHRISTINA.LIU@GS.COM

its partnership with natural gas turbine supplier GEV. She sees the addition of a new CEO in April as paving the way for a unified strategic path to more sustainable growth.

For **HII**, Noah Poponak sees a pure play on US Navy Shipbuilding, at a time where the Pentagon and US government have decided to allocate substantial funding to growing the Navy and improving its industrial base. HII has seen strong demand for Navy ships for years, but has been unable to deliver all of the units due to labor throughput. Demand is now set to grow to even higher heights under the current DoD budget plan and Poponak sees those labor challenges improving. All in, he sees accelerating top-line growth, expanding margins, and improved free cash flow conversion in the near-to-medium term. His 2026 EPS is 6% above Street estimates.

For **KTB**, Brooke Roach believes the denim maker's recently completed acquisition of ski and sail-wear brand, Helly Hansen, strengthens and diversifies its existing portfolio, enabling it to expand into new, and growing, categories (outdoor/active/outerwear) and internationally. This new growth, coupled with healthy underlying trends in its base business (particularly Wrangler), creates an attractive growth profile – all while being relatively insulated from tariffs. Roach is above the Street on FY2 EPS.

## Market Commentary - so much for sell in May...

Several things that markets have feared like deglobalization, rising trade barriers, and immigration reform's impact on labor supply have not yet had a notable impact on the pace of US economic growth as Kamakshya Trivedi and Dominic Wilson highlight in Sunday's Global Markets Views, "[Stirred, but not Shaken](#)." Indeed, even after our economists cut our 2Q25 GDP growth tracker by 10bp Friday, it is still growing at close to a 4% pace. And while many have feared that hiring will slow precipitously in the face of so much policy uncertainty, so far it has not. May non-farm Payroll additions came in at 139,000 — well below the pace we saw through most of the Biden Administration era, but still near the trend employment level needed to hold unemployment at bay.

Interestingly, against this backdrop, David Mericle and team raised our Fed funds rate cut forecast to 3 cuts this year from only 1 previously, and we now think the Fed will start cutting in September and keep cutting until we get down to a 3-3.25% terminal rate — 50bp lower than our prior forecast — in "[Shifting to a September Cut and a Lower Terminal Rate](#)." Why the dovish tilt from our economists? Tariff-driven inflation appears to be less than we first anticipated. But the labor market may be eroding just as much as we thought it would. While the labor market still looks healthy, it has become hard to find a job, and both residual seasonality and immigration policy changes pose near-term downside risk to payrolls. So like we saw in 2019, look for the Fed to start 'insurance cuts' in September and cut again in October and December and twice more in 2026.

Finally, on the macro front, while markets were aided throughout June by (mostly) encouraging data releases, July provides another month to climb the wall of worry — with this week alone offering two critical rungs on the ladder (a fresh ISM Manufacturing survey on Tuesday and the June Payrolls report on Wednesday — see "[US Week Ahead: June 30 - July 6](#)"). And next week, of course, includes the July 9th tariff pause end date — potentially another big test for tariff levels.

All of this solidifies the notion that markets are currently in what is now an extended 'wall of worry' climb. We sat down with Shawn Tuteja, who oversees ETF and custom baskets volatility trading within Goldman Sachs Global Banking & Markets division to discuss how this wall of worry provides a path to even greater gains (click into our weekly podcast, "[The Markets: Climbing the 'Wall of Worry'](#)"). And Trivedi and Wilson also highlighted this dynamic in the Global Markets Views note, "[Stirred, but not Shaken](#)." They write that the recent conflict in the Middle East is a reminder both that new policy shocks can surface, but also that unless the worst outcomes materialize, they can create only a higher wall for markets to climb — as we saw throughout June. But they also remind us that as markets relax again, other risks may move back into focus: fresh tariff news, potential for more visible weakening in the US growth and jobs data, or the upcoming fiscal package.

And beyond the macro, June also saw the further resurgence of some of the themes that had met headwinds earlier this year, from AI to robotaxis, US power expansion, and beyond. Here are a few themes that are drawing our attention as we head into summer.

- **AI.** 1Q result and NVDA's earnings in late May highlighted how the infrastructure build-out phase of the AI revolution is continuing. Mark Delaney actually raised estimates for data center enablers in a Jun-9 note, "[Datacenter market continues to show strength; modestly raising estimates and price targets for select companies.](#)" And we also saw progress in the transition to the AI application phase as Jim Covello and Eric Sheridan highlighted in the Jun-24 note, "[Analyzing the Impact of AI on Industry Profit Pools – Part I \(Advertising Case Study\)](#)" and Gabriela Borges and team highlighted in a separate note, "[Generative AI Part XI: Agentic AI expands the App Software TAM.](#)" To be truly successful, we see a need for AI to disrupt meaningful existing profit pools — not just cut costs. And we identify Advertising — agencies and Ad Tech — as one such pool. We also illustrate how well-positioned software companies are already employing AI Agents (think souped-up chat bots) to help customers navigate increasingly robust software solutions. We sat down with both teams to discuss the state of AI and capture the conversations in two podcasts: "[Research Unplugged: Addressing the Impact of AI on Industry Profit Pools – Advertising Deep Dive](#)" and "[Research Unplugged: AI Agents: Sizing the Software Opportunity.](#)" CL stocks with ties to the AI theme: PINS, UBER, GEV, AND T.
- **Robotaxis.** Mark Delaney and team lay out a path to a \$7bn autonomous rideshare market by 2030 in "[Framing profit pools in rideshare, trucking, and insurance as AVs move from concept to commercialization.](#)" The market opportunity is starting from a super low base and is not as great as the one that Allen Chang and team laid out for China in a May-6 note, "[China's Robotaxi market - the road to commercialization.](#)" But technology has a way of making step changes. And TSLA's launch of its Robotaxi service in late June provides further visibility on the path to scale as Delaney highlighted in "[TSLA: Tesla begins robotaxi operations - initial takeaways.](#)" We sat down with Delaney, Chang, Eric Sheridan and others to discuss the growing Robotaxi theme in mid-June and capture the conversation in the podcast, "[Research Unplugged: Autonomous Vehicles: From concept to commercialization and the path to profitability.](#)" CL stocks to focus on: UBER.
- **Defense of the future.** The Trump Administration continued to push Europe towards accepting more of the financial burden of its military defense throughout the month and our economists weighed in on Europe's progress in a series of notes: "[Germany—Budget Announcement Suggests a More Frontloaded Fiscal Boost](#)"; "[EU—Defence Spending: Why Markets Don't Feel SAFE Yet](#)"; and "[UK—How Large is the Defence Dividend?](#)" And Anthony Valentini gave the theme some US equity teeth on Jun-30 with the coverage launch of the US Defense Tech sector in a comprehensive report, "[Defense Tech: Launching Defense Tech as industry transformation is under way; Buy AVAV, KTOS, DRS, CAE.](#)" The Ukraine conflict proved that large volumes of low-cost, technologically acceptable systems can combat exquisite platforms at a fraction of the cost. And we believe Defense is in the early stages of a major structural change that will drive disruptive Defense Tech companies taking a larger share of global defense spending.
- **Power.** Earlier in June, Carly Davenport reiterated our forecast that US power demand will grow at a 2.5% CAGR through 2030 in "[Power demand growth on track](#)"

despite macro uncertainty; maintain 2.5% CAGR." Some have grown concerned that interruptions to AI, EV's, and the Manufacturing Renaissance will derail the electrification of America. But we still see an uninterrupted path with demand even skewed to the upside. In 1Q25, for example, weather normal demand grew by 2.9% on average, on strong commercial and residential demand. Later in June, Brian Lee and team highlighted the emerging opportunity to increase existing nuclear power plant capacity by 'uprating' facilities through a variety of initiatives, including upgrading existing equipment to produce more power — see the Jun-25 note, "Nuclear: Power uprates a potential driver of near- to medium-term upside for the nuclear value chain; Buy CCJ." CL stocks to focus on: DUK and GEV.

- **Obesity.** We kicked off June with our annual Global Health Care Conference in Miami and later in the month the American Diabetes Association (ADA) held their own conference. And LLY is coming out of the month with a series of successes that Asad Haider believes solidifies the GLP-1 producer in the obesity prevention lead (see the Jun-23 note, "LLY: Impressive ubiquity at ADA reinforces pole position in obesity"). We also sat down with doctors to discuss the potential of the new drugs that LLY and others are developing to treat obesity and capture our findings in a Jun-24 note, "Pharmaceuticals: KOL dinner frames ADA updates for LLY, NOVO, and AMGN." We sat down with our entire Healthcare research team to discuss obesity and a whole lot more on the heels of our conference and capture the conversation in a 60-minute podcast, "Research Unplugged: Takeaways from our 46th Annual Global Healthcare Conference."
- **M&A.** June may have marked a structural shift in what had been relatively dormant capital markets. Going into the month, panelists on our healthcare investment banker panel noted that the M&A market for BioPharma deals remained depressed (see the Jun-11 note, "Global Healthcare: 46th Annual Global Healthcare Conference — Notes from GS Investment Banker Panel"). But since then, both LLY and BNTX announced new acquisitions (see "Lilly Announces Acquisition of Verve" and "BNTX Announces Acquisition of CureVac").
- **Deregulation.** Signs of a lighter corporate touch from the Federal government emerged in June as well. In particular, the CCAR Bank capital requirement results released on Friday came in significantly better than expected lowering capital requirements by 40bp more than forecast and providing no bank with an increased capital requirement as Richard Ramsden and team discussed in "2025 CCAR: Structurally lower CET1 requirements, as SCBs move lower, with changes to the test appearing permanent." CL stocks to focus on: COF, BAC, HLI, and RJF.

**Catalyst corner.** As we head into July and deep summer, a flurry of catalysts also lie ahead that could compel stocks higher or conversely, provide a broken rung on the wall of worry ladder that causes risk assets to fall. Beyond this week's and next week's macro catalysts (ISM, Payrolls, Jul-9 tariff pause deadline), we also face a few others, including:

- **2Q25 earnings season.** Consensus is looking for only 4% yoy EPS growth in 2Q as margins contract qoq, but David Kostin expects the S&P 500 in aggregate will beat this low bar in Friday's Kickstart, "Look for early impact of tariffs during 2Q 2025"

earnings season."

- **Budget bill.** Congress will continue to refine its budget bill and Alec Phillips thinks it may be passed in late July/early August (see the Jun-17 note, "[USA: Senate Fiscal Bill: Near-term Fiscal Effects Similar to House Bill but 10-Year Cost Likely Higher](#)").
- **The Fed.** The FOMC meets on Jul-29 and 30th with a statement due out on the afternoon of the 30th. Trivedi and team point out that a dovish tilt from the Fed amidst anemic inflation and still OK growth could reinforce an upside case for risk assets (see note above). And while we do not expect the Fed to cut rates at the July meeting, we now do look for the central bank to begin cutting again at the next meeting after this one, in September (see Mericle's note above).
- **AI.** The hyperscalers — GOOGL, MSFT, AMZN — report towards the end of July or on the first day of August, providing another datapoint around the durability of the AI infrastructure trade.

# Conviction List - what has worked, what has not and what has changed

We provide performance of each name on the list for the month of June and the life-to-date total return relative to the S&P 500 Index and the S&P 500 equal-weighted Index in the table below. Additionally, we present the Conviction List "hit rate" – a simple measure of the performance that calculates the percentage of stocks that have outperformed the stated benchmark during their time on the list, since inception. Lastly, we provide commentary on select names that saw strength and weakness during the month and highlight the names that were added to and removed from the list.

## Exhibit 2: Conviction List - Directors' Cut stock performance

June and life-to-date returns

Ticker	Name	Calendar Days on the List	June 2025	Life-to-Date Return Rel to S&P 500	Life-to-Date Return Rel to EW S&P 500
INSM	Insmet Inc.	301	44.3%	20.5%	26.3%
PINS	Pinterest Inc.	273	15.3%	2.0%	7.9%
COF	Capital One Financial Corp.	29	12.5%	7.4%	9.0%
GEV	GE Vernova	91	11.9%	62.5%	68.0%
UBER	Uber Technologies Inc.	180	10.9%	48.5%	49.9%
OLED	Universal Display Corp.	29	8.1%	3.0%	4.6%
BAC	Bank of America Corp.	148	7.9%	0.1%	2.2%
ALNY	Alnylam Pharmaceuticals Inc.	148	7.1%	16.9%	18.9%
SPX	S&P 500		5.1%		
<sup>1</sup>	GS Americas Coverage		4.8%		
RJF	Raymond James Financial Inc.	148	4.3%	-12.0%	-9.9%
T	AT&T Inc.	91	4.1%	-7.5%	-2.0%
SPW	S&P 500 Equal Weight		3.4%		
HLI	Houlihan Lokey Inc.	61	3.4%	-0.3%	3.5%
AL	Air Lease Corp	211	1.9%	12.7%	18.2%
PM	Philip Morris International Inc.	334	1.6%	50.6%	56.5%
OS	OneStream Inc.	29	0.9%	-4.2%	-2.6%
DE	Deere & Co.	120	0.8%	1.8%	4.6%
BAX	Baxter International Inc.	120	-0.7%	-16.5%	-13.7%
JNJ	Johnson & Johnson	61	-1.6%	-13.1%	-9.4%
KGS	Kodiak Gas Services Inc.	91	-2.9%	-17.9%	-12.4%
VNOM	Viper Energy Inc.	120	-3.9%	-20.4%	-17.6%
MAA	Mid-America Apartment Communi	29	-5.5%	-10.6%	-8.9%

## <sup>2</sup> Conviction List hit rate (n = 87 LTD; n=53 TTM)

Relative to:	LTD	TTM
S&P 500	49%	51%
S&P 500 Equal Weight	55%	58%
GICS Sector	54%	58%
GS Americas Coverage	56%	60%

## Added to the list this month

Ticker	Name	Days on the List	June 2025	LTD Return Rel to SP500
DUK	Duke Energy Corp.			
KTB	Kontoor Brands Inc.			
HII	Huntington Ingalls Industries			

## Removed from the list this month

Ticker	Name	Days on the List	June 2025	LTD Return Rel to SP500	LTD Return Rel to EW SP500	Date removed
NET	Cloudflare	91	18.0%	62.8%	68.3%	7/1
SNOW	Snowflake Inc.	365	8.8%	50.5%	52.9%	7/1
WWD	Woodward Inc.	334	13.3%	44.3%	50.1%	7/1

<sup>1</sup> Total return for Americas Research coverage

<sup>2</sup> Hit rate is defined as the % of stocks that have outperformed the benchmark while on the list, since inception

Source: Goldman Sachs Global Investment Research, Bloomberg

## What has worked

**INSM (+).** The drug company reported positive topline data from a key Ph2b trial (TPIP PAH - in patients with pulmonary arterial hypertension), with the study meeting all primary and secondary efficacy endpoints. Notably, the results were consistent with Andrea Newkirk's bull case scenario, which she details in her June-10 note "INSM: Positive Ph2b TPIP PAH data surpass expectations." Newkirk also reviews her dinner and fireside chat at the GS Healthcare conference in her June-12 note "INSM: 46th Annual Global Healthcare Conference — Key Takeaways" and came away incrementally more positive on the outlook for adoption of TPIP post her KOL discussion which she highlights in her 6-18 note "KOL discussion underscores TPIP's and Winrevair's clinical profiles amidst an evolving PAH landscape." Next up is the August 12th PDUFA.

**COF (+).** Ryan Nash highlights Capital One Financial as one of the biggest beneficiaries of the Fed's 2025 CCAR stress tests among regional banks and consumer finance companies with its SCB (Stress Capital Buffer) decreasing by 90 bps, and that's before considering the DFS merger which Nash expects will likely result in a lower SCB down the road for the combined entity. June-27: "2025 CCAR: Structurally lower CET1 requirements, as SCBs move lower, with changes to the test appearing permanent".

**WWD (+).** The aircraft aftermarket part manufacturer saw continued strength in June (+13%) after a strong May (+15%) during which Noah Poponak came away from a management group lunch and meetings at the 2025 Paris Air Show with high conviction that aerospace aftermarket fundamentals remain strong (units, price and pent-up demand) and in WWD's unique content gain story with the LEAP. He provides takeaways in the May-19 "WWD: Company meeting takeaways: multiple growth and margin drivers across the business; Buy (on CL)" and the June-20 "2025 Paris Air Show takeaways".

## What has not

**MAA (-).** The apartment REIT underperformed this month on market fears that macro/policy uncertainty may have an impact on consumer/renter sentiment during peak leasing season (May to August).

## What has changed

With this update we add Duke Energy (DUK), Huntington Ingalls (HII) and Kontoor Brands (KTB) to the US Conviction List. We remove Cloudflare (NET), Snowflake (SNOW) and Woodward (WWD), all of which remain Buy-rated. As discussed in previous monthly updates, there are many reasons a stock could get removed from the list. They can include (but are not limited to) analysts no longer having conviction in their idea (e.g. a downgrade), price realization, the passage of catalysts or the subcommittee believing there are better opportunities elsewhere. In short, names will be removed if the committee determines a name is no longer a top investment idea (list will target 20-25 Buy-rated stocks) across the Americas coverage.

Importantly, inclusion on this list is not a stock rating and addition to or removal from this list does not necessarily represent a change in the analyst's investment rating for such stock.

**Exhibit 3: Conviction List Changes since May 31st, 2025**  
Changes to FY2 EPS, Price Targets and to the List

Ticker	Name	FY2 EPS %	PT %
KGS	Kodiak Gas Services Inc	-9%	-2%
BAC	Bank Of America Corp	0%	13%
BAX	Baxter International Inc	3%	-5%
INSM	Insmmed Inc	0%	12%
GEV	GE Vernova Inc	0%	14%

CL Additions		Date
KTB	Kontoor Brands Inc	7/1/2025
DUK	Duke Energy Corp	7/1/2025
HII	Huntington Ingalls Industries	7/1/2025

CL Removals		Date
NET	Cloudflare Inc - Class A	7/1/2025
SNOW	Snowflake Inc-Class A	7/1/2025
WWD	Woodward Inc	7/1/2025

Source: Goldman Sachs Global Investment Research, Bloomberg

For the exclusive use of CHRISTINA.LIU@GS.COM

# Anatomy of the List

## Top 5 Snapshot

While our Conviction List process focuses on stocks where our analysts expect strong risk-adjusted returns, we recognize there are a broad range of investing styles across portfolio managers. Below, we highlight the top five stocks from the current Conviction List across four major metrics: Upside to 12-month price target, Upside to next year's consensus EPS, FY2 Revenue growth and current Dividend Yield.

### Exhibit 4: The Conviction List contains stocks that are attractive across a number of metrics

Top 5 by fundamental metric

Upside to price target		Upside to consensus EPS		Revenue Growth		Dividend Yield	
VNOM	47%	INSM	>20%	INSM	133%	VNOM	6%
MAA	30%	VNOM	>20%	VNOM	27%	KGS	5%
KTB	29%	ALNY	>20%	ALNY	24%	MAA	4%
KGS	25%	OS	11%	OS	21%	T	4%
BAX	22%	KTB	8%	UBER	15%	DUK	4%

Source: Company data, Goldman Sachs Global Investment Research

## By the Numbers

Our Conviction List should not be viewed as a portfolio as we will not attempt to weight these stocks or ensure diversification across our stock coverage. That said, we will continue to provide some context of the list construction to give investors a taste of the independent investment ideas on the list.

### Exhibit 5: By the Numbers

16%	3%	8%
median upside to price target	median upside to consensus FY2 KPI	median FY2 revenue growth
26%	78%	0.9
% names with 50% or less Street Buy	% names with upside to FY2 KPI	median beta

Source: Goldman Sachs Global Investment Research, Bloomberg

## Upcoming Catalysts

Below we provide a rolling calendar of select earnings and non-earnings catalysts that have the potential to drive investor sentiment toward our analysts' view.

**Exhibit 6: Earnings-day option implied moves**

Current option implied moves relative to 8 quarter average actual moves

Ticker	Date	Earnings-day move		Implied minus historical
		Current Implied +/-	8Q Avg actual +/-	
BAC	16-Jul	2%	3%	-1%
PM	22-Jul	3%	4%	-2%
T	23-Jul	2%	4%	-2%
MTH	23-Jul	5%	5%	0%
RJF	23-Jul	4%	3%	1%
GEV	23-Jul	7%	3%	4%
PINS	28-Jul	10%	13%	-4%
ALNY	30-Jul	9%	5%	4%
BDC	30-Jul	5%	7%	-2%
AL	30-Jul	6%	5%	0%
HII	30-Jul	7%	9%	-2%
KTB	30-Jul	2%	7%	-5%
SPGI	31-Jul	2%	4%	-2%

Source: Goldman Sachs Global Investment Research

**Exhibit 7: Non-earnings catalysts our analysts expect to be important**

Potential non-earnings events

Ticker	Date	Event
INSM	12-Aug	Brensocatib - Potential U.S. approval and subsequent launch in non-CF bronchiectasis
ALNY	2H25	ROG-partnered zilebesiran in hypertension (Ph2 combination data and Ph3 initiation)
INSM	2H25	TPIP - Initiation of Ph3 PH-ILD study (with initiation of Ph3 PAH study to follow)
ALNY	2H25	Mivelsiran - Additional Ph1 data in Alzheimer's
INSM	YE25	Brensocatib - Topline Ph2b data in chronic rhinosinusitis without nasal polyps (CRSsNP)

Source: Company data, Goldman Sachs Global Investment Research

## Conviction List Explained - refrain

On June 1, 2023 we introduced this new investment list which highlights a selection of fundamental Buy-rated US stocks across the Goldman Sachs Americas Global Investment Research department. These ideas are sourced from our US research analysts, but chosen by members of our Investment Review Committee. This new 'Conviction List - Directors' Cut' is designed to provide investors with a curated and active list of 20-25 of what we believe to be our most differentiated fundamental Buy ideas across our US stock coverage.

The subcommittee, which includes the Americas Director of Research and the other senior research managers listed as authors of this report, will collaborate with each sector analyst to identify top ideas that offer a combination of conviction, a differentiated view and high risk-adjusted returns. The subcommittee will then choose what they view as the top 20-25 ideas across the department for the list. We intend to refresh and publish the list monthly to allow the list to become part of the investment process of Portfolio Managers.

Importantly, we do not express thematic or factor views with this list. Rather, this list focuses on bottom-up fundamental analysis from our analysts. While our analysts will incorporate their view of macro impacts on the fundamentals of their stocks, we will not intentionally express factor, rates, inflation or other macro views in the construction of this list. Our analysts appropriately incorporate the impact of these factors in their estimates which are a critical component to our selection process.

Finally, inclusion on this list is not a stock rating and addition to or removal from this list does not necessarily represent a change in the analyst's investment rating for such stock.

### Recent Editions:

- ["US Conviction List - Directors' Cut: June 2025 - Two Years On"](#)
- ["US Conviction List - Directors' Cut: May 2025 Update"](#)
- ["US Conviction List - Directors' Cut: January 2025 Update: Top Themes for the Year Ahead"](#)
- Inaugural Edition: 6/1/23: ["Conviction List - Directors' Cut"](#)

Visit the Conviction List – Directors' Cut portal page here: ["Americas Conviction List — Directors' Cut"](#)

### Recent Podcasts:

- ["Research Unplugged: US Conviction List - Directors' Cut: June 2025 Stock Spotlight – OLED, COF, OS & MAA"](#)
- ["Research Unplugged: US Conviction List - Directors' Cut: June 2025 Spotlight – Two Years On"](#)
- ["Research Unplugged: US Conviction List - Directors' Cut: May Spotlight"](#)

## Our 23 most differentiated Buy recommendations

The company specific discussion in the sections below reflect the views of the covering analyst.

### Exhibit 8: Conviction List - Directors' Cut

Ticker	Company	Summary
<b>Consumer</b>		
KTB	Kontoor Brands Inc	Strong brand momentum with attractive growth opportunity
PM	Philip Morris International	Leading the cigarette industry to a smoke-free future
<b>Financials</b>		
BAC	Bank Of America Corp	A deregulation beneficiary levered to an expanding economy
COF	Capital One Financial Corp	Merger synergy story with network effects and a big buyback
HLI	Houlihan Lokey Inc	The right time for an acquisitive restructuring specialist
MAA	Mid-America Apartment Comm	Sunbelt migration beneficiary at a good time in the supply cycle
RJF	Raymond James Financial Inc	Strong earnings outlook with exposure to a Capital Markets recovery
<b>Healthcare</b>		
ALNY	Alnylam Pharmaceuticals Inc	Catalyst-rich biotech company on the edge of an inflection
BAX	Baxter International Inc	Optimizing a profitable footprint
INSM	Insmed Inc	A product portfolio company emerging - at an inflection point
JNJ	Johnson & Johnson	Navigating a patent cliff to a higher stock price
<b>Industrial</b>		
AL	Air Lease Corp	A critical cog in a supply constrained airplane market
DE	Deere & Co	Close to as bad as it is likely to get; an inflection story
GEV	GE Vernova Inc	Dominant position to electrify America
HII	Huntington Ingalls Industries	Pure play on Pentagon's prioritization of the Navy
<b>Natural Resources</b>		
DUK	Duke Energy Corp	Well-positioned with regulators, suppliers, and its own management team
KGS	Kodiak Gas Services Inc	An underappreciated steady cash flow compounder with a dominant market position
OLED	Universal Display Corp	Product cycle on steroids as OLED rolls out the color blue
VNOM	Viper Energy Inc	Asset Light, Scaling Permian Pure Play
<b>TMT</b>		
OS	Onestream Inc	Early-stage growth compounder modernizing the Office of the CFO
PINS	Pinterest Inc- Class A	Well-positioned profitable compounder in the digital advertising space
T	AT&T	Earnings upside from market discipline and broadband growth to drive valuation upside
UBER	Uber Technologies Inc	A disruptor not yet ready to be disrupted

Source: Goldman Sachs Global Investment Research

## Duke Energy Corp. (DUK) - covered by Carly Davenport

*Well-positioned with regulators, suppliers, and its own management team*

DUK is making regulatory progress that should support strong growth in the Carolinas and Florida. Additionally, as the utility ramps up its development of greater electricity generation capacity, capex should be supported by its partnership with nat gas turbine supplier GEV which should provide it with better access to gas turbines — critical to actually building the new power capacity. Finally, Davenport believes the addition of a new CEO in April paves the way for a unified strategic path to more sustainable growth.

- **GEV partnership provides capex advantage.** Building out new electrical generation capacity has become expensive and time-consuming – given supply chain constraints. But DUK's ability to build at scale with its partnership with GEV gives it a competitive advantage to bring on gas generation quicker and more cost effectively than its peers. DUK and GEV recently announced the utility secured 19 natural gas turbines to meet growing demand needs into the 2030s. Duke expects to spend \$83 bn in capex over the next five years, with about 45% going towards the grid and about 40% going towards new generation.
- **Regulatory clarity emerges.** Key constraints for DUK have been its challenged balance sheet due to regulatory lag and the storms that occur in the company's service territory. But the improved regulatory environment in the company's service territories have paved the way for DUK to become a more premium utility due to the supportive earnings growth and the ability to recover costs in a timely manner. In particular, a favorable allowed return for a competing utility in South Carolina in a recent rate case, and a favorable outcome for a DUK rate case in Florida puts DUK on a better path to higher and more predictable returns.
- **Discounted valuation.** DUK currently trades at a 6% discount to premium peers, in line with the historical discount average. But DUK is positioned to grow earnings faster than it has in the past – 8% CAGR versus 5-year historical growth rate of 3% – suggesting that it should see multiple expansion to the premium peer average. FactSet consensus EPS estimates are also marginally below GS estimates.

### Where we are different.

Davenport's estimates are 2% above consensus, on average, in 2025-2028. She is more optimistic on execution under a new CEO on the regulatory side of the business, as well as the balance sheet, which should both be supportive of above trend earnings growth going forward relative to history. Davenport believes the progress the company has made on regulatory mechanisms and ROEs, as well as the load growth and capex opportunities in its service territories, including the ability to build more gas in the near term, should solidify DUK as a premium utility from a valuation perspective.

### Valuation.

12-month target price of \$132 is based on 19x P/E multiple on Q5-Q8 GS estimates. Key downside risks include: DUK's balance sheet not improving as expected; regulatory

uncertainty from its recently filed rate case at Duke Energy Progress; and any decline in the strong load growth forecast impacting expected earnings growth.


### Catalysts.

DUK reaching its FFO/debt leverage target this year at 14% as it executes on financing plans, recovers storm costs, and monetizes nuclear PTCs; reaching a constructive resolution on the recently filed rate case at Duke Energy Progress in South Carolina, where hearings are expected to begin in 4Q25; execution on EPS results and power generation asset additions on time; potential upside around the load growth/capex/earnings outlook on the 4Q25 earnings call could all be positive catalysts for shares.

### Key Chart.

**Exhibit 9: Davenport expects DUK EPS to grow at a 8% CAGR through 2029**

DUK 2024 EPS and GSe for EPS in 2025-2029



Source: Goldman Sachs Global Investment Research

### Relevant Research.

- Jun-25: "Nuclear: Power uprates a potential driver of near- to medium-term upside for the nuclear value chain; Buy CCJ"
- Jun-25: "Utilities: Follow the EPS growth in large cap utilities; DUK to Buy, WEC to Sell, AEE up to Neutral"
- Jun-8: "Utilities: Power demand growth on track despite macro uncertainty; maintain 2.5% CAGR"

## Huntington Ingalls Industries Inc. (HII) - covered by Noah Poponak

### *Pure play on Pentagon's prioritization of the Navy*

HII is a pure play on US Navy Shipbuilding, at a time where the Pentagon and US government have decided to allocate substantial funding to growing the Navy and improving its industrial base. HII has seen strong demand for Navy ships for years, but has been unable to deliver all of the units due to labor throughput. Demand is now set to grow to even higher heights under the current DoD budget plan. Those labor challenges have also impacted margins due to productivity in the yards. However, the Navy has now awarded HII funding specifically to be able to improve hiring and retention. Noah Poponak expects HII to see accelerating top-line growth, expanding margins, and improved free cash flow conversion in the near-to-medium term, on the back of this increased focus and funding from its customer.

- **A faster top-line.** The Pentagon wants a larger Navy, and HII is one of only two companies in the world producing world class ships that meet military naval standards. Nuclear powered submarines and aircraft carriers are force multipliers given their capability compared to cost. Backlog growth has been substantial, and should not flow faster to revenue if labor throughput improves.
- **Substantial margin expansion potential.** HII margins are at their lowest point in a decade as pandemic driven labor turnover has driven productivity challenges. The company needs to hire, train, and retain, which has been difficult in recent periods. However, the Pentagon and US government are now raising the priority level of the Navy, including specifically wanting to improve the industrial base and its labor force. In April the Pentagon awarded HII \$1.3bn for the purpose of improving labor, including higher wages. Poponak expects HII to soon start seeing better labor metrics, which can flow directly to margins, for a stock that has always been highly correlated to profitability performance.
- **A low bar.** Market expectations are low for HII following the margin challenges experienced last year. The investor bar is low, just at a time when the customer is looking to fund improvements in the challenges the company has faced. He thinks there is substantial upside potential to sell-side consensus estimates, and many potential incremental buyers of the stock given how left behind this has become in recent periods.

### **Where we are different.**

Poponak's 2025/2026/2027 EPS are 5%/7%/10% above consensus, and his 2027 free cash is 23% above the Street. His deep dive into the Navy budget, and into the executive order on maritime shipbuilding, gives him confidence in a growth acceleration and margin expansion in the forward. The stock has a low bar when considering the sell-side analyst ratings distribution.

### **Valuation.**

12-month price target of \$265 is derived from a target relative (S&P 500) CY26E P/E of


1.0X. Key risks include: (1) Geopolitics, (2) DoD spending priorities, (3) margins.

Catalysts.

Poponak expects HII to be able to provide improved labor metrics over the near-term as they report earnings. He also expects margins to improve through the year. HII was recently awarded funding to improve labor productivity, and we expect additional awards similar to that, and for more ships, over the next several months. We expect consensus estimates to move higher.

Key Charts.

Exhibit 10: Poponak expects Shipbuilding margins to recover  
% adjusted EBIT margin



Source: Company data, Goldman Sachs Global Investment Research

For the exclusive use of CHRISTINA.LIU@GS.COM

**Exhibit 11: Shipbuilding spending proposed in the current reconciliation language**

		Enhancement of DoD Resources for Shipbuilding	
\$mn Requested		Purpose	
\$	250	Expansion of accelerated Training in Defense Manufacturing program	
\$	250	U.S. production of turbine generators for shipbuilding industrial base	
\$	450	U.S. additive manufacturing for wire production and machining capacity for shipbuilding industrial base	
\$	492	Next-generation shipbuilding techniques	
\$	85	U.S.-made steel plate for shipbuilding industrial base	
\$	50	Machining capacity for naval propellers for shipbuilding industrial base	
\$	110	Rolled steel and fabrication facility for shipbuilding industrial base	
\$	400	Expansion of collaborative campus for naval shipbuilding	
\$	450	Application of autonomy and artificial intelligence to naval shipbuilding	
\$	500	Adoption of advanced manufacturing techniques in the maritime industrial base	
\$	500	Additional dry-dock capability	
\$	50	Expansion of cold spray repair technologies	
\$	450	Additional maritime industrial workforce development programs	
\$	750	Additional supplier development across the naval shipbuilding industrial base	
\$	250	Additional advanced manufacturing processes across the naval shipbuilding industrial base	
\$	4,600	A second Virginia-class submarine in GFY27	
\$	5,400	Two additional Guided Missile Destroyer (DDG) ships	
\$	160	Advanced procurement for Landing Ship Medium	
\$	1,804	Procurement of Landing Ship Medium	
\$	295	Development of a second Landing Craft Utility shipyard and production of additional Landing Craft Utility	
\$	100	Procurement of commercial logistics ships	
\$	600	Lease or purchase of new ships through the National Defense Sealift Fund	
\$	2,725	Procurement of T-AO oilers	
\$	500	Cost-to-complete for rescue and salvage ships	
\$	300	Production of ship-to-shore connectors	
\$	695	Implementation of a multi-ship amphibious warship contract	
\$	80	Accelerated development of vertical launch system reloading at sea	
\$	250	Expansion of Navy corrosion control programs	
\$	159	Leasing of ships for Marine Corps operations	
\$	1,534	Expansion of small unmanned surface vessel production	
\$	1,800	Expansion of medium unmanned surface vessel production	
\$	1,300	Expansion of unmanned underwater vehicle production	
\$	188	Development and testing of maritime robotic autonomous systems and enabling technologies	
\$	174	Development of a Test Resource Management Center robotic autonomous systems proving ground	
\$	250	Development, production, and integration of wave-powered unmanned underwater vehicles	
\$	2,100	San Antonio-class Amphibious Transport Dock (LPD)	
\$	3,700	America-class Amphibious Assault Ship (LHA)	
\$	33,751	<b>Total: Enhancement of DoD Resources for Shipbuilding</b>	

Source: House Armed Services Committee, Data compiled by Goldman Sachs Global Investment Research

**Relevant Research.**

- May-28: "HII: Management meeting takeaways: substantially increased support of US Navy shipbuilding is underway; Buy"
- May-1: "HII: Better margins in quarter, plus Navy shipyard investment put on contract; Buy"
- April-11: "Aerospace & Defense: Shifting less cautious in defense as medium-term budget picture shapes up; Buy HII, LHX"

## Kontoor Brands Inc. (KTB) - covered by Brooke Roach

*Strong brand momentum with attractive growth opportunity*

Brooke Roach believes the denim maker's recently completed acquisition of ski and sail-wear brand, Helly Hansen, strengthens and diversifies its existing portfolio, enabling it to expand into new, and growing, categories (outdoor/active/outerwear) and internationally. This new growth, coupled with healthy underlying trends in its base business (particularly Wrangler), creates an attractive growth profile – all while being relatively insulated from tariffs.

- **Portfolio Diversification into the Right End Markets.** Roach believes the addition of Helly Hansen to the portfolio transforms KTB's potential long-term growth and margin profile, driving a faster top-line growth outlook and providing opportunity for stronger FCF over time. Helly Hansen remains underpenetrated in the US, and Roach outlines the margin and growth opportunity as the company scales HH and integration synergies are realized.
- **The Jeans that Built America.** Beyond HH, Roach highlights brand momentum in KTB's base business. The Wrangler brand is demonstrating particular strength, driven by solid execution, strategic investments/partnerships, and demand for western wear more broadly. Additionally, Roach sees signs of stabilization in KTB's Lee brand ahead following a reset.
- **Idiosyncratic Tariff Insulation.** While Roach expects tariffs to weigh on KTB's profitability in the near term, she believes the company is well-positioned to navigate the volatile global trade and macro backdrop as a third of its production is in Mexico and it has limited exposure to China.

### Where we are different.

Roach is more constructive on the integration opportunity for the Helly Hansen brand vs. consensus, and our work suggests significant AUR and sales upside supported by margin tailwinds as a result of synergies. Her analysis suggests the Helly Hansen brand is underpenetrated vs. peers in KTB's core US market, particularly given its average relative price point, and she expects KTB management to leverage their prior operating experience in the outdoor market. This, combined with ongoing momentum at Wrangler on the back of healthy western trends and sequentially improving results at Lee, drives her higher earnings growth forecasts versus consensus.

### Valuation.


12-month target price of \$85 is based on a 10.5x Q5-Q8 EV/EBITDA valuation multiple, which reflects a ~1x premium to current trading levels due to our stronger conviction in the company's growth and margin outlook. Key downside risks include: (1) Execution missteps regarding the integration of the Helly Hansen asset; (2) Slower western trends following several years of stronger growth; (3) A longer path to Lee brand stabilization than we anticipate; (4) Key customer concentration (WMT); (5) Weaker than expected margin tailwinds, including mix shift and Helly Hansen margin expansion.

Catalysts.

Following the completion of the acquisition of the Helly Hansen brand, investor focus moving forward is centered on earnings results, including updates on Helly Hansen integration, recent momentum at the Wrangler brand, and Lee brand stabilization. Roach also expects KTB to be a relative outperformer on any tariff news on Vietnam given the company’s more limited exposure to that sourcing market. Finally, she sees scope for KTB to host an investor day and provide an update on the long-term trajectory of the business at some point over the next several quarters (after sufficient time has passed post the Helly Hansen acquisition), though this is not officially scheduled at this juncture.

Key Charts.


Exhibit 12: Roach believes KTB’s expansion into outerwear significantly expands the company’s TAM



Source: Euromonitor

Exhibit 13: Roach believes Helly Hansen has ample opportunity to scale in the US (and globally), particularly given the company’s attractive price/value positioning

2024 US sales at retail estimates per Euromonitor (\$mn) vs. jacket AUR (GSe; excl. promotions; RHS)



GSe for Helly Hansen US sales at retail: assumes a 1.5x wholesale markup, US represents 25% of HH sales, and wholesale represents ~73% of HH sales.

Source: Euromonitor, Company data, Goldman Sachs Global Investment Research

Relevant Research.

- Jun-10: “KTB: Attractive growth profile with idiosyncratic opportunity; reinstate at Buy”

For the exclusive use of CHRISTINA.LIU@GS.COM

# Disclosure Appendix

## Reg AC

We, Steven Kron, Chris Hussey, John Marshall and Sarah Herr, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

## GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

**Growth** is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

## M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

## Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

## Disclosures

**The rating(s) for Huntington Ingalls Industries Inc. and Woodward Inc. is/are relative to the other companies in its/their coverage universe:**

AeroVironment Inc., Amentum Holdings, Boeing Co., Bombardier Inc., Booz Allen Hamilton, CACI International Inc., CAE Inc., Ducommun Inc., Embraer, GE Aerospace, General Dynamics Corp., Heico Corp., Hexcel Corp., Howmet Aerospace Inc., Huntington Ingalls Industries Inc., Kratos, L3Harris Technologies Inc., Leidos Holdings, Leonardo DRS, Lockheed Martin Corp., Mercury Systems Inc., Northrop Grumman Corp., Parsons Corp., Planet Labs, RTX Corp., Rocket Lab Corp., Science Applications International, Teledyne Technologies Inc., Textron Inc., TransDigm Group, V2X Inc., Virgin Galactic Holdings, Wheels Up, Woodward Inc.

**The rating(s) for Duke Energy Corp. is/are relative to the other companies in its/their coverage universe:** Ameren Corp., American Electric Power, Consolidated Edison Inc., Dominion Energy Inc., Duke Energy Corp., Edison International, Eversource Energy, Exelon Corp., FirstEnergy Corp., NextEra Energy Inc., PG&E Corp., Public Service Enterprise Group, Sempra, Southern Co., Vistra Corp., WEC Energy Group, Xcel Energy Inc.

**The rating(s) for Snowflake Inc. is/are relative to the other companies in its/their coverage universe:** Adobe Inc., Atlassian Corp., Autodesk Inc., Bentley Systems Inc., Confluent Inc., CoreWeave Inc., Datadog Inc., Definitive Healthcare Corp., Dropbox Inc., Dynatrace Inc., Elastic NV, GitLab Inc., Intuit Inc., Microsoft Corp., Monday.Com Ltd., MongoDB Inc., Oracle Corp., PagerDuty, Procore Technologies Inc., RingCentral, Rubrik Inc., Salesforce Inc., Samsara Inc., ServiceNow Inc., ServiceTitan Inc., Snowflake Inc., Twilio, Unity Software Inc., Weave Communications Inc., Workday Inc., Zoom Video Communications Inc., ZoomInfo Technologies Inc.

**The rating(s) for Kontoor Brands Inc. is/are relative to the other companies in its/their coverage universe:** Amer Sports Inc., Burlington Stores Inc., Canada Goose Holdings, FIGS Inc., Gap Inc., Groupe Dynamite Inc., Kohl's Corp., Kontoor Brands Inc., Levi Strauss & Co., Lululemon Athletica Inc., Macy's Inc., Nike Inc., PVH Corp., Ralph Lauren Corp., Ross Stores Inc., Savers Value Village Inc., SharkNinja, Inc., TJX Cos., Tapestry Inc., Torrid Holdings Inc., VF Corp., Victoria's Secret & Co., Warby Parker Inc., YETI Holdings

**The rating(s) for Cloudflare is/are relative to the other companies in its/their coverage universe:** AvePoint, BigCommerce Holdings, Braze Inc., CCC Intelligent Solutions Holding, Check Point, Clearwater Analytics Holdings, Cloudflare, CrowdStrike, DigitalOcean Holdings, EverCommerce Inc., Fortinet, HubSpot Inc., Kaltura Inc., Klaviyo, Okta, Olo Inc., Palantir Technologies, Palo Alto Networks, SailPoint Inc., SentinelOne, Shopify Inc., Tyler Technologies Inc., Veeva Systems Inc., Zeta Global, Zscaler

## Option Specific Disclosures

**Price target methodology:** Please refer to the analyst's previously published research for methodology and risks associated with equity price targets.

**Pricing Disclosure:** Option prices and volatility levels in this note are indicative only, and are based on our estimates of recent mid-market levels (unless otherwise noted). All prices and levels exclude transaction costs unless otherwise stated.

**General Options Risks** – The risks below and any other options risks mentioned in this research report pertain both to specific derivative trade recommendations mentioned and to discussion of general opportunities and advantages of derivative strategies. Unless otherwise noted, options strategies mentioned in this report may be a combination of the strategies below and therefore carry with them the risks of those strategies.

**Buying Options** - Investors who buy call (put) options risk loss of the entire premium paid if the underlying security finishes below (above) the strike price at expiration. Investors who buy call or put spreads also risk a maximum loss of the premium paid. The maximum gain on a long call or put spread is the difference between the strike prices, less the premium paid.

**Selling Options** - Investors who sell calls on securities they do not own risk unlimited loss of the security price less the strike price. Investors who sell covered calls (sell calls while owning the underlying security) risk having to deliver the underlying security or pay the difference between the security price and the strike price, depending on whether the option is settled by physical delivery or cash-settled. Investors who sell puts risk loss of the strike price less the premium received for selling the put. Investors who sell put or call spreads risk a maximum loss of the difference between the strikes less the premium received, while their maximum gain is the premium received.

**For options settled by physical delivery**, the above risks assume the options buyer or seller, buys or sells the resulting securities at the settlement price on expiry.

Company-specific regulatory disclosures

Compendium report: please see disclosures at <https://www.gs.com/research/hedge.html>. Disclosures applicable to the companies included in this compendium can be found in the latest relevant published research

Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe

	Rating Distribution				Investment Banking Relationships		
	Buy	Hold	Sell		Buy	Hold	Sell
Global	49%	34%	17%		63%	57%	42%

As of April 1, 2025, Goldman Sachs Global Investment Research had investment ratings on 3,016 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.

Price target and rating history chart(s)

Compendium report: please see disclosures at <https://www.gs.com/research/hedge.html>. Disclosures applicable to the companies included in this compendium can be found in the latest relevant published research

Regulatory disclosures

Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with subject company, public appearances and trading securities held by the analysts.

**Distribution of ratings:** See the distribution of ratings disclosure above. **Price chart:** See the price chart, with changes of ratings and price targets in prior periods, above, or, if electronic format or if with respect to multiple companies which are the subject of this report, on the Goldman Sachs website at <https://www.gs.com/research/hedge.html>.

Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Brazil:** Disclosure information in relation to CVM Resolution n. 20 is available at <https://www.gs.com/worldwide/brazil/area/gir/index.html>. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 951-A, Rational House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India, Corporate

Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details can be found at this link: <https://publishing.gs.com/disclosures/hedge.html - /general/equity>. **Japan:** See below. **Korea:** This research, and any access to it, is intended only for "professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

**European Union and United Kingdom:** Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at <https://www.gs.com/disclosures/europeanpolicy.html> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

**Japan:** Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, The Investment Trusts Association, Japan, and Japan Investment Advisers Association. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

## Ratings, coverage universe and related definitions

**Buy (B), Neutral (N), Sell (S)** Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks.

**Total return potential** represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

**Coverage Universe:** A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at <https://www.gs.com/research/hedge.html>.

**Not Rated (NR).** The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. **Early-Stage Biotech (ES).** An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company neither has a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. **Rating Suspended (RS).** Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. **Coverage Suspended (CS).** Goldman Sachs has suspended coverage of this company. **Not Covered (NC).** Goldman Sachs does not cover this company.

## Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or [contatogoldmanbrasil@gs.com](mailto:contatogoldmanbrasil@gs.com). Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou [contatogoldmanbrasil@gs.com](mailto:contatogoldmanbrasil@gs.com). Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

**European Economic Area:** GSI, authorised by the PRA and regulated by the FCA and the PRA, disseminates research in the following jurisdictions within the European Economic Area: the Grand Duchy of Luxembourg, Italy, the Kingdom of Belgium, the Kingdom of Denmark, the Kingdom of Norway, the Republic of Finland and the Republic of Ireland; GSI - Succursale de Paris (Paris branch) which is authorised by the French Autorité de contrôle prudentiel et de résolution ("ACPR") and regulated by the Autorité de contrôle prudentiel et de résolution and the Autorité des marchés financiers ("AMF") disseminates research in France; GSI - Sucursal en España (Madrid branch) authorized in Spain by the Comisión Nacional del Mercado de Valores disseminates research in the Kingdom of Spain; GSI - Sweden Bankfilial (Stockholm branch) is authorized by the SFSA as a "third country branch" in accordance with Chapter 4, Section 4 of the Swedish Securities and Market Act (Sv. lag (2007:528) om värdepappersmarknaden) disseminates research in the Kingdom of Sweden; Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research in the Federal Republic of Germany and those jurisdictions within the European Economic Area where GSI is not authorised to disseminate research and additionally, GSBE, Copenhagen Branch filial af GSBE, Tyskland, supervised by the Danish Financial Authority disseminates research in the Kingdom of Denmark; GSBE - Sucursal en España (Madrid branch) subject (to a limited extent) to local supervision by the Bank of Spain disseminates research in the Kingdom of Spain; GSBE - Succursale Italia (Milan branch) to the relevant applicable extent, subject to local supervision by the Bank of Italy (Banca d'Italia) and the Italian Companies and Exchange Commission (Commissione Nazionale per le Società e la Borsa "Consob") disseminates research in Italy; GSBE - Succursale de Paris (Paris branch), supervised by the AMF and by the ACPR disseminates research in France; and GSBE - Sweden Bankfilial (Stockholm branch), to a limited extent, subject to local supervision by the Swedish Financial Supervisory Authority (Finansinspektionen) disseminates research in the Kingdom of Sweden.

## General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (<https://www.sipc.org>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at <https://www.theocc.com/about/publications/character-risks.jsp> and <https://www.fiadocumentation.org/fia/regulatory-disclosures/fia-uniform-futures-and-options-on-futures-risk-disclosures-booklet-pdf-version-2018>. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

**Differing Levels of Service provided by Global Investment Research:** The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to <https://research.gs.com>.

Disclosure information is also available at <https://www.gs.com/research/hedge.html> or from Research Compliance, 200 West Street, New York, NY 10282.

© 2025 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative

works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.

For the exclusive use of CHRISTINA.LIU@GS.COM